文献速递遗传性与小管间质肾病

PKD1剂量逻辑:RNA调控与治疗性去抑制

The Dosage Logic of PKD1: RNA Regulation and Therapeutic Derepression.
PubMed 文献 · J Am Soc Nephrol · 2026-10-26

综述整合遗传、分子与治疗证据,支持常染色体显性多囊肾病(ADPKD)的剂量阈值模型:残余PKD1等位基因输出不足驱动囊肿形成。PKD1的5'和3'非翻译区通过转录后机制限制多囊蛋白-1产量,3'UTR含保守miR-17结合位点;遗传或药理抑制miR-17可提高多囊蛋白剂量并减轻实验模型中的囊性疾病。抗miR-17寡核苷酸Farabursen的早期临床药效学发现与多囊蛋白-1/2去抑制一致,正推进至3期开发。

要点

  • ADPKD由PKD1杂合突变和功能性多囊蛋白-1剂量不足驱动,存在剂量阈值模型。
  • PKD1转录本的非翻译区主动限制蛋白生产,3'UTR含可治疗干预的miR-17位点。
  • 抑制miR-17可提高多囊蛋白剂量并减轻实验模型囊性疾病,Farabursen已进入3期。

核心结论

  • 内源性转录本去抑制是突变无关的恢复ADPKD基因剂量策略,并为其他剂量敏感遗传病提供框架。

研究设计与样本

  • 综述整合遗传、分子和治疗证据,支持ADPKD囊肿发生的剂量阈值模型。

主要发现

  • PKD1基因结构、RNA加工和蛋白成熟决定功能性多囊蛋白-1水平。
  • PKD1的5'和3'非翻译区通过转录后机制控制多囊蛋白-1产量。
  • 3'UTR含保守microRNA结合位点,包括可治疗干预的miR-17位点。
  • 遗传破坏或药理抑制miR-17可增加多囊蛋白剂量并减轻实验模型中的囊性疾病。
  • Farabursen的早期临床药效学发现与多囊蛋白-1和多囊蛋白-2去抑制一致,正推进至3期开发。

临床怎么用

  • 关注miR-17抑制作为突变无关的ADPKD治疗策略,恢复多囊蛋白剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal dominant polycystic kidney disease (ADPKD) is driven largely by heterozygous PKD1 mutations and insufficient functional polycystin-1 dosage, yet the mechanisms that regulate output from residual PKD1 alleles are only beginning to be defined. The PKD1 locus is unusually complex, and its transcript contains untranslated regions that actively constrain protein production. This review integrates genetic, molecular, and therapeutic evidence supporting a dosage-threshold model of cystogenesis. We discuss how gene architecture, RNA processing, and protein maturation set functional polycystin-1 levels, then focus on post-transcriptional control by the PKD1 5' and 3' untranslated regions. The 3'UTR contains conserved microRNA-binding sites, including a therapeutically actionable miR-17 site. Genetic disruption or pharmacologic inhibition of miR-17 increases polycystin dosage and attenuates cystic disease in experimental models. Farabursen, an anti-miR-17 oligonucleotide, has produced early clinical pharmacodynamic findings consistent with polycystin-1 and polycystin-2 derepression and is advancing into Phase 3 development. Together, these findings establish endogenous transcript derepression as a mutation-agnostic strategy for restoring gene dosage in ADPKD and provide a framework for treating other dosage-sensitive genetic disorders.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Ostrosky Frid M, Patel V. The Dosage Logic of PKD1: RNA Regulation and Therapeutic Derepression. J Am Soc Nephrol. 2026. PMID: 42931824. doi:10.1681/ASN.0000001316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。